Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astellas Pharma ( (JP:4503) ) has issued an announcement.
Astellas Pharma announced that its Phase 2 GLEAM trial, which investigated the combination of zolbetuximab with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer, did not meet its primary endpoint of overall survival. Despite this setback, Astellas remains committed to advancing its research in pancreatic cancer, recognizing the significant challenges associated with this aggressive disease. The company plans to further evaluate the trial data and continue its efforts to develop innovative treatments, with the financial impact of the trial’s outcome expected to be minor.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1600.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas Pharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of innovative therapies. The company focuses on oncology, urology, immunology, and other therapeutic areas, with a strong emphasis on developing treatments for difficult-to-treat diseases such as pancreatic cancer.
YTD Price Performance: 10.94%
Average Trading Volume: 7,118,688
Technical Sentiment Signal: Buy
Current Market Cap: Yen2919B
Find detailed analytics on 4503 stock on TipRanks’ Stock Analysis page.